Weifa ASA: Record second-quarter revenues driven by pain and cough & cold
(Thomson Reuters ONE) -
Oslo, 13 July 2017
* Record second-quarter revenues of NOK 98.6 million (NOK 95.3 million)
* All-organic growth of 3.4%
* Second-quarter adjusted EBITDA of NOK 22.1 million (NOK 18.6 million)
* Adjusted EBITDA margin of 22.5% (19.5%)
* Record first-half revenues of NOK 198.2 million (NOK 191.5 million)
* Organic growth of 3.5%
* Strong brands secured revenue growth and high market shares in the main
categories
Weifa ASA (OSE: WEIFA) had record second-quarter revenues in 2017 on higher
sales within pain relief and cough & cold products. Total revenues for the
quarter was NOK 98.6 million, representing an all-organic growth of 3.4%
compared with the same period of 2016.
EBITDA was NOK 21.1 million (NOK 17.1 million) for the second quarter after NOK
1.1 million (NOK1.4 million) in cost of employee options. The EBITDA margin
adjusted for these costs was 22.5% (19.5%). Weifa's portfolio of long-
established brands maintained a high market share in all key segments during the
quarter.
"We are on track to deliver on our revenue growth ambitions for 2017 with record
revenue for both the second quarter and first half of 2017. We continue to
develop our leading position in the Norway across our portfolio, and we look
forward to developing our Nordic offering going forward" says CEO Kathrine
Gamborg Andreassen.
Revenue for the first half of 2017 was NOK 198.2 million, an increase of 3.5%
from the same period in 2016. The organic growth was driven by increased demand
for pain and cough and cold products.
Weifa will give a presentation today at 08:30 CET at Felix Konferansesenter,
Bryggetorget 3, Oslo, Norway. CEO Kathrine Gamborg Andreassen and CFO Simen
Nyberg-Hansen will represent the company. The presentation will also be webcast
live and can be accessed directly from:
http://webtv.hegnar.no/presentation.php?webcastId=58376211
http://www.weifa.no/webcast
Questions may be submitted live during the presentation.
Please find the report and presentation for the second quarter enclosed. The
report and presentation will also be made available on www.weifa.no.
For further information, please contact:
Kathrine Gamborg Andreassen
CEO
+47 95 17 86 80
kathrine.gamborg.andreassen(at)weifa.no
Simen Nyberg-Hansen
CFO
+47 98 20 63 55
Simen.nyberg-hansen(at)weifa.no
Weifa is Norway's leading consumer health company. We supply real value through
medicines, lifestyle products and solutions that address the essential needs of
consumers, customers and professional partners. Weifa was founded in 1940 and
now employs about 30 highly qualified people at our headquarters in Oslo. The
company has a strong position in Norway and is the market leader in pain relief,
with well-established brands such as Paracet and Ibux. We are also present in
other key areas such as dietary supplements and treatment for colds and
respiratory problems. Weifa is listed on the Oslo Børs (ticker WEIFA). For
further information, please visit: www.weifa.no
This information is subject to the disclosure requirements pursuant to section
5-12 of the Norwegian Securities Trading Act.
Weifa ASA_2Q 2017_Presentation:
http://hugin.info/136972/R/2120060/807560.pdf
Weifa ASA_2Q 2017_Report:
http://hugin.info/136972/R/2120060/807561.pdf
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Weifa ASA via GlobeNewswire
Unternehmensinformation / Kurzprofil:
Datum: 13.07.2017 - 07:30 Uhr
Sprache: Deutsch
News-ID 552176
Anzahl Zeichen: 4086
contact information:
Town:
Oslo
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 305 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Weifa ASA: Record second-quarter revenues driven by pain and cough & cold"
steht unter der journalistisch-redaktionellen Verantwortung von
Weifa ASA (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
